AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2023
Jan 6, 2023
31523_dirs_2023-01-06_b6a072df-7062-409d-a193-8b2d74a80522.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-01-04
Reporting Person: Clark David Michael (Chief People Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-04 | Common Stock | F | 2692 | $12.03 | Disposed | 241073 | Direct |
| 2023-01-06 | Common Stock | S | 21507 | $11.8727 | Disposed | 219566 | Direct |
Footnotes
F1: The sale of common stock was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.75 to $11.98. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.